NCT03831971View on ClinicalTrials.gov

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 1, 2019

Primary Completion Date

August 9, 2019

Study Completion Date

December 30, 2019

Conditions
Opiod Use Disorder
Interventions
DRUG

ANS-6637

Subjects will receive (1) midazolam 5 mg po single dose on Day 1 followed by (2) Drug free period on Day 2 followed by (3) ANS-6637 600 mg po daily (Days 3-7) to reach steady state followed by (4) ANS-6637 600 mg po single dose + midazolam 5mg po single dose on Day 8

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

National Institutes of Health Clinical Center (CC)

NIH

NCT03831971 - The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers | Biotech Hunter | Biotech Hunter